Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo para avaliar a segurança e a eficácia do IPN10200 em participantes adultos com linhas faciais superiores moderadas a graves (LANTIC)

2 de outubro de 2026 atualizado por: Ipsen

Um estudo de fase Ib/II, multicêntrico, duplo-cego, randomizado, controlado por placebo, escalonamento de dose e determinação de dose para avaliar a segurança e a eficácia do IPN10200 na melhora da aparência de linhas faciais superiores moderadas a graves em adultos

The purpose of this study is to assess the safety and efficacy profile of increasing doses of Corabotase (also known as IPN10200) in comparison to placebo, with the aim to discover the doses(s) that offer the best efficacy/safety profile when used for the treatment of moderate to severe Upper Facial Lines.

This study will be conducted in three stages. The full study (including all stages) will have a maximum 727 participants.

Stage 1 (phase Ib & II)

  • Step 1 (Phase Ib): a dose-escalation first-in-human step in participants with moderate to severe Glabellar Lines (GL)
  • Step 2 (Phase II): dose ranging step in participants with moderate to severe GL as compared with Dysport
  • Step 3 (Phase II): dose finding step in participants with moderate to severe GL as compared with Dysport, followed by an open label (OL) phase for the highest dose cohort to assess the long-term safety and efficacy of Corabotase. In the OL phase, participants may receive repeat administrations of Corabotase for up to three additional cycles (up to four treatment cycles in total during the study).

Stage 2 (phase II) - An evaluation of efficacy and safety of Corabotase in one of the following regions: GL + forehead lines (FHL), forehead lines (FHL) or lateral canthal lines (LCL)

Stage 3 (phase II)

- A safety and efficacy evaluation of Corabotase in all three regions (GL, FHL and LCL)

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

727

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Berlin, Alemanha, 13353
        • CRS Clinical Research Services Berlin GMBH
      • Berlin, Alemanha
        • Interdisciplinary Study Association
      • Darmstadt, Alemanha
        • ROSENPARK RESEARCH GmbH
      • Düsseldorf, Alemanha
        • Privatpraxis Dr. Hilton & Partner
      • Hamburg, Alemanha
        • Fachbereich Chemie Institut für Biologie und Molekularbiologie Studiengang Kosmetikwissenschaft
      • Mahlow, Alemanha
        • Dermatologische Gemeinschaftspraxis Blankenfelde-Mahlow
    • State of Berlin
      • Kassel, State of Berlin, Alemanha
        • Interdisciplinary Study Association
      • Antibes, França
        • MEDITI - Clinique Del Mar
      • Lyon, França
        • Aimed S.A.S
      • Paris, França
        • Clinique de Chirurgie Esthétique Iéna

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Participant must be 18 to 65 years of age inclusive, at the time of signing the informed consent.
  2. Moderate or severe (Grade 2 or 3) GL (Stage 1) at maximum contraction at Baseline, as assessed by the ILA using a validated 4-point photographic scale.
  3. Moderate or severe (Grade 2 or 3) GL (Stage 1) at maximum contraction at Baseline, as assessed by the SSA using a validated 4-point categorical scale.
  4. Moderate or severe (Grade 2 or 3) FHL (Stage 2) at maximum contraction and moderate to severe GL at maximum contraction at Baseline or moderate to severe (Grade 2 or 3) LCL (Stage 2) at maximum contraction (Stage as assessed by the ILA using a 4-point photographic scale).
  5. Moderate or severe (Grade 2 or 3) FHL (Stage 3) at maximum contraction and moderate to severe GL at maximum contraction at Baseline and moderate to severe (Grade 2 or 3) LCL (Stage 3) at maximum contraction (Stage as assessed by the ILA using a 4-point photographic scale).
  6. Moderate or severe (Grade 2 or 3) FHL (Stage 2) at maximum contraction and moderate to severe GL maximum contraction at Baseline or moderate to severe (Grade 2 or 3) LCL (Stage 2) at maximum contraction as assessed by the SSA using a 4-point photographic scale.
  7. Moderate or severe (Grade 2 or 3) FHL (Stage 3) at maximum contraction and moderate to severe GL maximum contraction at Baseline and moderate to severe (Grade 2 or 3) LCL (Stage 3) at maximum contraction, as assessed by the SSA using a 4-point photographic scale.
  8. Dissatisfied or very dissatisfied (Grade 2 or 3) with their lines (Stages 1 to 3) at Baseline, as assessed by the SLS.
  9. Male and female participants (only female for Stage 1/Step 1). Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  10. Capable of giving signed informed consent includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  11. Participant has both the time and the ability to complete the study and comply with study instructions.
  12. Does not reside in an institution by administrative or court order.
  13. Is not a sponsor employee or clinical research unit personnel directly affiliated with the study or is not an immediate family member. Immediate family is defined as a spouse, parent, child or sibling whether biological or legally adopted.

Exclusion Criteria:

  1. An active infection or other skin problems in the upper face including the GL, FHL, and LCL area (e.g. acute acne lesions or ulcers).
  2. A history of eyelid blepharoplasty or brow lift within the past 5 years
  3. A history of facial nerve palsy.
  4. Marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin.
  5. Any known medical condition that may put the participant at increased risk in regard to exposure to BoNT of any serotype (i.e. myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, etc.)
  6. Has COVID-19 illness or a known positive SARS-CoV-2 test (Stage 1), or the presence of any other condition (e.g. neuromuscular disorder or other disorder that could interfere with neuromuscular function)
  7. Previous treatment with any BoNT serotype for Stage 1 / Step 1 or any recent treatment (within the past 9 months prior to baseline) with any BoNT serotype for Stage 1 / Step 2, Stage 1/Step 3, Stages 2 and 3. Participants treated in earlier Stages/Steps of the study must not be included in any later Stages/Steps.
  8. Any prior treatment with permanent fillers in the upper face including the GL, FHL and LCL area.
  9. Any prior treatment with long lasting dermal fillers or any permanent procedures in the upper face inclusion the GL area within the past 3 years and/or skin abrasions/resurfacing (whatever the interventional technic used) within the past 5 years, or photo rejuvenation or skin/vascular laser intervention within the 12 months prior to Baseline.
  10. Any planned facial cosmetic surgery during the study.
  11. Use of concomitant therapy which, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study intervention. Therapy considered necessary for the participant's welfare may be given at the discretion of the investigator.
  12. Use of medications that affect neuromuscular transmission, such as curare-like non depolarising agents, lincosamides, polymyxins, anticholinesterases, aminoglycoside antibiotics and systemic retinoids, within the past 30 days prior to baseline are prohibited or a longer washout period of at least five half-lives might be required, as deemed appropriate by the investigator for longer-acting medications. Topical use of for example aminoglycoside medications or topical retinoids on the face apart from the area of injection would be acceptable.
  13. Use of any experimental device within 30 days or use of any treatment with an experimental drug within five times the documented terminal half-life of the respective drug or its metabolites or if the halflife is unknown within 30 days prior to the start of the study (prior to Baseline) and during the conduct of the study.
  14. Known positive for hepatitis B antigen, or hepatitis C virus antibody, or for human immunodeficiency virus (HIV) or a diagnosis of acquired immunodeficiency syndrome.
  15. Clinically diagnosed significant anxiety disorder, or any other significant psychiatric disorder (e.g. depression) that might interfere with the participant's participation in the study
  16. An inability to substantially lessen GL and/or horizontal forehead rhytids even by physically spreading them apart as determined by the investigator.
  17. Known allergy or hypersensitivity to BoNT or any excipients of IPN10200 or Dusport/Azzalure, or allergy to cow's milk protein.
  18. A history of drug or alcohol abuse
  19. Pregnant women, nursing women, premenopausal women or women of childbearing potential not willing to practice a highly effective form of contraception method
  20. Male participants who are not vasectomized and who have female partners of childbearing potential and are not willing to use condoms with spermicide throughout study participation.
  21. Any uncontrolled systemic disease or other significant medical condition which would be harmful for the participant to be entered into the study or continue participation.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Grupo Dysport (apenas estágio 1 / etapa 2 e 3)

Single administration of study intervention in stage 1 / step 2 and 3 only

Experimental: Corabotase group

Stage 1/Step 1: Several cohorts of participants will be randomized in a ratio of 3:1 (Corabotase:placebo)in a dose-escalation manner. The decision to escalate to the next dose for each cohort will be based on Data Monitoring Committee (DMC) recommendation.

Stage 1/Step 2: parallel dose-ranging manner Stage 1/Step 3: each cohort will include three treatment groups randomised in a ratio of 4:1:1 (Corabotase: placebo:dysport) The decision to escalate to the next dose for each cohort will be based on DMC recommendation .

Stage 2: the dose(s) chosen for administration in each region of the face will be selected on the basis of the intermediate analyses of Stage 1/Step 3. Participants will be randomised for each group in a ratio of 4:4:1 (Corabotase:Corabotase:placebo).

Stage 3: total dose for each region defined in Stages 1 and 2. Participants will be randomised for each group in a ratio of 3:1.

Stage 1: Several different doses will be administrated in a dose-escalation manner.

One single injection will be injected locally into several sites across the glabellar region.

Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions.

Stage 3: One single injection will be injected locally into several sites across the upper facial area.

Comparador de Placebo: Placebo group

Stage 1/Step 1: Several cohorts of participants will be randomized in a ratio of 3:1 in a dose-escalation manner. The decision to escalate to the next dose for each cohort will be based on Data Monitoring Committee (DMC) recommendation.

Stage 1/Step 2: parallel dose-ranging manner Stage 1/Step 3: each cohort will include three treatment groups randomised in a ratio of 4:1:1 (Corabotase:Corabotase: placebo) The decision to escalate to the next dose for each cohort will be based on DMC recommendation.

Stage 2: the dose(s) chosen for administration in each region of the face will be selected on the basis of the intermediate analyses of Stage 1/Step 3. Participants will be randomised for each group in a ratio of 4:4:1 (Corabotase:Corabotase:placebo).

Stage 3: total dose for each region defined in Stages 1 and 2. Participants will be randomised for each group in a ratio of 3:1.(Corabotase:placebo)

Stage 1: One single injection of study intervention will be injected locally into several sites across the glabellar region.

Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions.

Stage 3: One single injection will be injected locally into several sites across the upper facial area.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Incidence of treatment emergent adverse events (TEAEs) at each dose
Prazo: From the baseline to the end of the study (9 months)

At Stage 1/Step 1, Stage 3

From the baseline to the end of the study (9 months)
Incidence of serious adverse events (SAEs) at each dose
Prazo: From the baseline to the end of the study (9 months)

At Stage 1/Step 1, Stage 3

From the baseline to the end of the study (9 months)
Incidence of Adverse Events (AEs) (or SAEs) leading to withdrawals and Adverse Events of Special Interest (AESIs)
Prazo: From the baseline to the end of the study (9 months)

At Stage 1/Step 1, Stage 3

From the baseline to the end of the study (9 months)
Response to treatment at Stage 2 for the FHL group
Prazo: At Week 4

Measured by the composite response of ≥ 2-grade improvement on Investigator's Live Assessment (ILA) and subject's self-assessment (SSA) at maximum contraction on the forehead lines:

ILA: a validated 4-point photographic scale to assess the severity and appearance of the Forehead Lines (FHL) at maximum frown and at rest where 0 is "none" and 3 is "severe"

SSA: a validated 4-point categorical scale to assess the appearance of their FHLs at maximum frown where 0 is "no wrinkles" and 3 is "severe wrinkles"

At Week 4
Response to treatment at Stage 2 for the glabellar lines (GL)+ FHL group
Prazo: At Week 4

Measured by the composite response of ≥ 2-grade improvement on ILA and SSA at maximum contraction on the forehead lines (FHL) area:

ILA: a validated 4-point photographic scale to assess the severity and appearance of the GLs and FHLs at maximum frown and at rest where 0 is "none" and 3 is "severe"

SSA: a validated 4-point categorical scale to assess the appearance of their GLs and FHLs at maximum frown where 0 is "no wrinkles" and 3 is "severe wrinkles"

At Week 4
Response to treatment at Stage 2 for the LCL group
Prazo: At Week 4

Measured by the composite response of ≥ 2-grade improvement ILA and SSA at maximum contraction on both sides of the lateral canthal lines (LCL) area:

ILA: a validated 4-point photographic scale to assess the severity and appearance of the LCLs at maximum frown and at rest where 0 is "none" and 3 is "severe"

SSA: a validated 4-point categorical scale to assess the appearance of their LCLs at maximum frown where 0 is "no wrinkles" and 3 is "severe wrinkles"

At Week 4
Percentage of Participants With Clinically Significant Changes from baseline in Vital Signs
Prazo: From the baseline to the end of the study (6 years, 5 months)

Double Blind phase. Clinically significant changes in vital signs will be reported. The clinical significance will be graded by the investigator.

From the baseline to the end of the study (6 years, 5 months)
Percentage of participants with clinically significant Change from baseline in 12-lead Electrocardiogram (ECG) readings
Prazo: From the baseline to the end of the study (6 years, 5 months)

Double Blind phase.

From the baseline to the end of the study (6 years, 5 months)
Percentage of participants with clinically significant change from baseline in facial and focused neurological/physical examination.
Prazo: From the baseline to the end of the study (6 years, 5 months)

Double Blind phase. Clinically significant changes in facial examination and focused neurological/physical examinations will be reported. The clinical significance will be graded by the investigator.

From the baseline to the end of the study (6 years, 5 months)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Resposta ao tratamento alcançada por uma pontuação de "muito satisfeito" ou "satisfeito" no Nível de Satisfação do Assunto (SLS)
Prazo: Desde a linha de base até o final do estudo (9 meses)
Desde a linha de base até o final do estudo (9 meses)
Percentage of participants response to treatment.
Prazo: From the baseline to the end of the study (up to 6 years, 5 months)

For all stages. Measured by the composite response of ≥ 2-grade improvement on ILA and SSA for each concerned facial area in each respective stage (GL/LCL/FHL)

ILA: a validated 4-point photographic scale to assess the severity and appearance of the GLs/LCLs/FHLs in each respective stage at maximum frown and at rest where 0 is "no lines are noticeable" and 3 is "lines are extremely pronounced"

SSA: a validated 4-point categorical scale to assess the appearance of their GLs/LCLs/FHLs in each respective stage at maximum frown where 0 is "no wrinkles" and 3 is "severe wrinkles"

From the baseline to the end of the study (up to 6 years, 5 months)
Percentage of participants response to treatment as measured by the reduction of ≥1 grade on the ILA at maximum contraction for each concerned facial area
Prazo: From the baseline to the end of the study (up to 6 years, 5 months)

For all stages.

From the baseline to the end of the study (up to 6 years, 5 months)
Percentage of participants with clinically significant change from baseline in facial and focused neurological/physical examination
Prazo: From the baseline to the end of the study (up to 6 years, 5 months)

For all stages. Clinically significant changes in facial examination and focused neurological/physical examinations will be reported. The clinical significance will be graded by the investigator.

From the baseline to the end of the study (up to 6 years, 5 months)
Percentage of participants response to treatment as achieved by a score of "none" or "mild" as measured by the ILA at rest on each facial area
Prazo: From the baseline to the end of the study (up to 6 years, 5 months)

For all stages

From the baseline to the end of the study (up to 6 years, 5 months)
Percentage of participants response to treatment as measured by the reduction of ≥1 grade on the SSA at maximum contraction for each concerned facial area
Prazo: From the baseline to the end of the study (up to 6 years, 5 months)

For all stages.

From the baseline to the end of the study (up to 6 years, 5 months)
Percentage of participants response to treatment as achieved by a score of "none" or "mild" as measured by the SSA at maximum contraction for each concerned facial area.
Prazo: From the baseline to the end of the study (up to 6 years, 5 months)

Stage 2 and Stage 3.

From the baseline to the end of the study (up to 6 years, 5 months)
Duration of treatment response based on ILA and SSA at maximum contraction for each concerned facial area
Prazo: From the baseline to the end of the study (up to 6 years, 5 months)

For all stages.

From the baseline to the end of the study (up to 6 years, 5 months)
Time to onset of treatment response based on subject diary cards to evaluate the appearance of their lines for each concerned facial area
Prazo: From the baseline to the end of the study (up to 6 years, 5 months)

For all stages.

From the baseline to the end of the study (up to 6 years, 5 months)
Satisfaction with facial appearance, measured by Facial Appearance Overall scale score on the Face-Q satisfaction scale
Prazo: From the baseline to the end of the study (up to 6 years, 5 months)

Stage 3. Face Q is a participant-reported outcome instrument to evaluate the experience and outcomes of aesthetic facial procedures from the participant's perspective. The Face Q instrument is composed of over 40 scales, covering four domains (Satisfaction with Facial Appearance, Health Related Quality of Life, Adverse Effects, and Process of Care).

From the baseline to the end of the study (up to 6 years, 5 months)
Satisfaction with facial appearance, measured by FACE-Q Short Form Facial Appearance scale score.
Prazo: From the baseline to the end of the study (6 years, 5 months)

Stage 3. The FACE-Q Short Form Facial Appearance scale is a participant-reported outcome instrument. It asks how dissatisfied or satisfied the participant is with their upper facial lines (UFL) (GL+FHL+LCL). The scale ranges from very dissatisfied to very satisfied.

From the baseline to the end of the study (6 years, 5 months)
Incidence, severity and nature of treatment emergent adverse events (TEAEs)
Prazo: From baseline to the end of the study (up to 6 years, 5 months)

All stages (except Stage 1/Step 1)

From baseline to the end of the study (up to 6 years, 5 months)
Incidence, severity and nature of serious adverse events (SAEs)
Prazo: From baseline to the end of the study (up to 6 years, 5 months)

All stages (except Stage 1/Step 1)

From baseline to the end of the study (up to 6 years, 5 months)
Incidence, severity and nature of Adverse Events (AEs) (or SAEs) leading to withdrawals and Adverse Events of Special Interest (AESIs)
Prazo: From baseline to the end of the study (up to 6 years, 5 months)

All stages (except Stage 1/Step 1)

From baseline to the end of the study (up to 6 years, 5 months)
Percentage of Participants With Clinically Significant Changes from baseline in Vital Signs
Prazo: From baseline to the end of the study (6 years, 5 months)

All stages (except Stage 1/Step 1). Clinically significant changes in vital signs will be reported. The clinical significance will be graded by the investigator.

From baseline to the end of the study (6 years, 5 months)
Time between two consecutive injections
Prazo: From baseline to the end of the study (up to 6 years, 5 months)

Stage 1/Step 3 .

From baseline to the end of the study (up to 6 years, 5 months)
Percentage of participants with binding antibodies to IPN10200
Prazo: At Week 4 , Week 24 and Week 36

Stage 1/Step 2, Stage 1/Step 3, Stage 2, and Stage 3

At Week 4 , Week 24 and Week 36
Percentage of participants with neutralising antibodies to IPN10200
Prazo: At Week 4 , Week 24 and Week 36

Stage 1/Step 2, Stage 1/Step 3, Stage 2, and Stage 3

At Week 4 , Week 24 and Week 36
Percentage of participants with binding antibodies to BontA
Prazo: At Week 4 , Week 24 and Week 36

Stage 1/Step 2, Stage 1/Step 3, Stage 2, and Stage 3

At Week 4 , Week 24 and Week 36
Percentage of participants with neutralising antibodies to BontA
Prazo: At Week 4 , Week 24 and Week 36

Stage 1/Step 2, Stage 1/Step 3, Stage 2, and Stage 3

At Week 4 , Week 24 and Week 36

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Ipsen Medical Director, Ipsen

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

6 de abril de 2021

Conclusão Primária (Estimado)

19 de agosto de 2027

Conclusão do estudo (Estimado)

19 de agosto de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

26 de março de 2021

Enviado pela primeira vez que atendeu aos critérios de CQ

26 de março de 2021

Primeira postagem (Real)

29 de março de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • D-FR-10200-002
  • 2024-512782-14-00 (Ctis)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Prazo de Compartilhamento de IPD

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Critérios de acesso de compartilhamento IPD

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever